170911-92-9Relevant articles and documents
Development of Novel Dihydrofuro[3,4- d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C
Kang, Dongwei,Sun, Yanying,Feng, Da,Gao, Shenghua,Wang, Zhao,Jing, Lanlan,Zhang, Tao,Jiang, Xiangyi,Lin, Hao,De Clercq, Erik,Pannecouque, Christophe,Zhan, Peng,Liu, Xinyong
, p. 2458 - 2470 (2022/02/05)
Here, we report the design, synthesis, structure-activity relationship studies, antiviral activity, enzyme inhibition, and druggability evaluation of dihydrofuro[3,4-d]pyrimidine derivatives as a potent class of HIV-1 non-nucleoside reverse transcriptase
Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via in Silico Design
Yokoo, Hidetomo,Shibata, Norihito,Endo, Akinori,Ito, Takahito,Yanase, Yuta,Murakami, Yuki,Fujii, Kiyonaga,Hamamura, Kengo,Saeki, Yasushi,Naito, Mikihiko,Aritake, Kosuke,Demizu, Yosuke
, p. 15868 - 15882 (2021/11/01)
Targeted protein degradation by proteolysis-targeting chimera (PROTAC) is one of the exciting modalities for drug discovery and biological discovery. It is important to select an appropriate linker, an E3 ligase ligand, and a target protein ligand in the
Indazole formamide compound as well as preparation method and application thereof
-
Paragraph 0035; 0048-0049; 0065; 0070-0071; 0137; 0141-0142, (2021/02/16)
The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce